Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody.
Ab affinity maturation in vivo is always accompanied by negative selection to maintain Ag specificity. In contrast, in vitro affinity maturation can lead to epitope spread, resulting in loss of specificity. Anti-ganglioside-GD2 mAbs are clinically effective against neuroblastoma; pain and neuropathy are major side effects. We used structural relatives of GD2 to define epitope spread during in vitro affinity maturation of an anti-GD2 single-chain variable fragment (scFv) called 5F11-scFv. Clonal dominance identified by polyclonal sequencing was confirmed by analyzing individual clones. Affinity-matured mutations were introduced into scFv-streptavidin for functional studies. Without a negative selector, 19-fold affinity improvement (clone Q, where Q is the symbol for glutamine) was associated with strong cross-reactivity with GM2 and GD1b and moderate cross-reactivity with GD3, resulting in positive immunohistochemical staining of all 13 non-neural normal human tissues, in contrast to none of 13 tissues with parental clone P. With GM2 as a negative selector, clone Y (where Y is the symbol for tyrosine) was generated with only weak cross-reactivity with GD1b, adrenal and thyroid glands, and no staining of other non-neural normal tissues. Even though there was only a 3-fold affinity improvement, clone Y showed significantly higher tumor uptake over parental clone P (134%, p = 0.04), whereas clone Q was inferior (54% of clone P; p = 0.05) as confirmed by tumor-to-normal tissue ratios across 16 organs (41% of clone P; p < 0.0001). Using the less efficient negative selector GD3, a clone mixture (Q, V, and Y, where V is the symbol for valine) emerged. We conclude that epitope spread during affinity maturation can be reduced by negative selection. Furthermore, efficiency of the negative selector depends on its cross-reactive affinity with the matured scFv.
Hu
Jian
J
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Huang
Xiaodong
X
Ling
Chang-Chun
CC
Bundle
David R
DR
Cheung
Nai-Kong V
NK
D000818:Animals; D000915:Antibody Affinity / Q000235:genetics; D000918:Antibody Specificity; D001483:Base Sequence; D001666:Binding Sites, Antibody / Q000235:genetics; D001667:Binding, Competitive; D002240:Carbohydrate Sequence; D002999:Clone Cells; D003429:Cross Reactions / Q000235:genetics / Q000276:immunology; D005732:Gangliosides / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D016056:Immunodominant Epitopes / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D019151:Peptide Library; D057127:Single-Chain Antibodies / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured
D005732:Gangliosides; D016056:Immunodominant Epitopes; D007135:Immunoglobulin Variable Region; D009844:Oligosaccharides; D019151:Peptide Library; D057127:Single-Chain Antibodies; C019403:ganglioside, GD2